When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Investors appear disappointed with Ligand Pharmaceuticals' (LGND-11.6%) agreement to sell its rights to Promacta (eltrombopag) to Royalty Pharma for $827M in cash. The company plans to reinvest the proceeds to acquire assets with long-term revenue streams, fully funded "shots on goal," technology platforms and share buybacks. The transaction should close today.
More news on: Ligand Pharmaceuticals Incorporated, Novartis AG, Healthcare stocks news, Stocks on the move,